The Annual International PfSPZ Consortium Met in Toronto, Canada

The Annual International PfSPZ Consortium Met in Toronto, Canada on November 8th & 9th, 2025

December 10, 2025 By In News No Comments
The 2025 iPfSPZ-C meeting brought together scientists from around the world to review an extraordinary year of progress in Plasmodium falciparum sporozoite (PfSPZ) vaccine and other SPZ research. Over a day and a half, 48 scientists from 11 countries presented major scientific breakthroughs, steady advances in product development, and coordinated plans for global evaluation of Sanaria’s PfSPZ-based malaria vaccines to the in-person participants and on-line participants around the world.
Read More

Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants

June 1, 2019 By In Publications No Comments

Abstract

In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria’s impact. Sanaria® PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria- na ̈ıve and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the United States and field transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore, evaluated PfSPZ Vaccine in 93 Tanzanians aged 45 years to 6 months |

Read More

Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine

January 2, 2013 By In Publications No Comments

Read the new paper published today in Vaccine.

Abstract

Typically, vaccines distributed through the Expanded Program on Immunization (EPI) use a 2-8°C cold chain with 4-5 stops. The PfSPZ Vaccine comprises whole live-attenuated cryopreserved sporozoites stored in liquid nitrogen (LN(2)) vapor phase (LNVP) below -140°C and would be distributed through a LNVP cold chain. The purpose of this study was to model LNVP cold chain distribution for the cryopreserved PfSPZ Vaccine in Tanzania, estimate the costs and compare these costs to those that would be incurred in distributing a ‘conventional’ malaria vaccine through the EPI. Capital and recurrent costs |

Read More

The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine

December 9, 2008 By In Publications No Comments
We are developing a radiation attenuated Plasmodium falciparum sporozoite (PfSPZ) malaria vaccine. An important step was to determine the minimum dose of irradiation required to adequately attenuate each sporozoite. This was studied in the Plasmodium yoelii rodent model system. Exposure to 100 Gy completely attenuated P. yoelii sporozoites (PySPZ).
Read More

News Categories

About Sanaria

Sanaria is a Maryland-based biotechnology company developing innovative vaccines that protect against malaria. We are focused on African children, the population most urgently in need of protection.

Latest News

Behind the Scenes: Vaccine Manufacturing

Contact Us

We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Email:

sanaria@sanaria.com

Social: